Gan & Lee Pharmaceuticals.
SHH: 603087.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Zhongru Gan
- Employees
- 4,482
- Headquarters
- Beijing, China
- IPO year
- 2020
- Market cap
- CN¥35.9B
- Website
- https://www.ganlee.com
Loading 603087…
Loading profile data…Frequently asked questions about 603087
What does Gan & Lee Pharmaceuticals. (603087.SS) do?
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30...
Where does 603087.SS trade?
Gan & Lee Pharmaceuticals. (603087.SS) trades on the Shanghai Stock Exchange.
What sector is 603087.SS in?
Gan & Lee Pharmaceuticals. (603087.SS) operates in the Healthcare sector, specifically in the Medical - Instruments & Supplies industry.
Who is the CEO of Gan & Lee Pharmaceuticals.?
Zhongru Gan is the chief executive officer of Gan & Lee Pharmaceuticals. (603087.SS).
Where is Gan & Lee Pharmaceuticals. headquartered?
Gan & Lee Pharmaceuticals. is headquartered in China.
Does 603087.SS pay a dividend?
Yes — Gan & Lee Pharmaceuticals. (603087.SS) paid a trailing twelve-month dividend of CNY 1.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603087.SS go public?
Gan & Lee Pharmaceuticals. (603087.SS) completed its initial public offering in 2020.